Time course of 75%-100% efficacy response of adjunctive brivaracetam
| Autor: | Cédric Laloyaux, Sami Elmoufti, Pavel Klein, Melinda S. Martin, Teresa Gasalla |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male focal epilepsy Time Factors Brivaracetam Placebo law.invention 03 medical and health sciences Epilepsy 0302 clinical medicine Randomized controlled trial Double-Blind Method law Seizures Post-hoc analysis medicine Humans sustained seizure reduction 030212 general & internal medicine Clinical Commentary antiepileptic drugs partial‐onset seizures Randomized Controlled Trials as Topic Seizure frequency business.industry Seizure types General Medicine Middle Aged medicine.disease Pyrrolidinones Treatment Outcome Neurology Clinical Trials Phase III as Topic Anesthesia Time course Anticonvulsants Drug Therapy Combination Female Neurology (clinical) focal to bilateral tonic‐clonic seizures business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Acta Neurologica Scandinavica |
| ISSN: | 1600-0404 |
| Popis: | BACKGROUND Time to sustained seizure frequency reduction can provide clinically meaningful epilepsy outcomes. AIMS OF THE STUDY To examine the time course of brivaracetam (BRV) efficacy in adults with focal seizures and focal to bilateral tonic-clonic seizures (FBTCS). METHODS Post hoc analysis of data pooled from three randomized controlled trials of oral adjunctive BRV in adults with epilepsy. Patients with focal epilepsy and a subpopulation with FBTCS receiving BRV 50, 100, or 200 mg/d (initiated without up-titration) or placebo for 12 weeks were analyzed for time to sustained ≥75%, ≥90%, and 100% seizure reduction without interruption from first day until trial ends. RESULTS Evaluation included 1160 patients with focal seizures, including 352 patients with FBTCS. Sustained ≥75%, ≥90%, and 100% response in focal seizures was higher from day 1 for BRV 100 and 200 mg/d vs placebo (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|